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Abstract
Human immunodeficiency virus type 2 (HIV-2) strains vary widely in their ability to grow in Old World monkey (OWM) cells. We previously
evaluated several HIV-2 isolates for their sensitivity to cynomolgus monkey (CM) TRIM5α, an anti-HIV factor in OWMcells, and found that viruses
carrying proline at the 120th position of the capsid protein were sensitive to CM TRIM5α, whereas those with either alanine or glutamine were
resistant. In the study presented here, we tested these HIV-2 isolates for their sensitivity to rhesus monkey (Rh) TRIM5α and found that both CM
TRIM5α-sensitive and -resistant viruses were restricted by Rh TRIM5α. The variable region 1 of the SPRY domain of Rh TRIM5α appeared to be
the determinant of this difference. Furthermore, a mutagenesis study showed that three amino acid residues TFP at the 339th to 341st positions of Rh
TRIM5α are important for restricting HIV-2 strains resistant to CM TRIM5α.
© 2007 Elsevier Inc. All rights reserved.Keywords: TRIM5α; Human immunodeficiency virus; Rhesus monkey; Cynomolgus monkeyIntroduction
Human immunodeficiency virus type 1 (HIV-1) has a very
narrow host range limited to humans and chimpanzees. Experi-
ments have demonstrated that HIV-1 does not infect Old World
monkeys (OWM) such as rhesus and cynomolgus monkeys.
Recently, the screening of a rhesus monkey cDNA library
identified tripartite motif 5α (TRIM5α) as a factor that confers
resistance to HIV-1 infection (Stremlau et al., 2004). Rhesus and
cynomolgus monkey TRIM5α restricts HIV-1 infection (Strem-
lau et al., 2004; Yap et al., 2004; Nakayama et al., 2005), whereas
human TRIM5α restricts N-tropic murine leukemia virus (N-
MLV) infection (Hatziioannou et al., 2004; Keckesova et al.,
2004; Perron et al., 2004). African green monkey (AGM)
TRIM5α restricts simian immunodeficiency virus isolated from⁎ Corresponding author. Fax: +81 6 6879 8347.
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doi:10.1016/j.virol.2007.12.022a macaque monkey (SIVmac), human immunodeficiency virus
type 2 (HIV-2), and equine infectious anemia virus in addition to
HIV-1 infection (Hatziioannou et al., 2004; Keckesova et al.,
2004; Nakayama et al., 2005). TRIM5α shares with other
splicing variants a common amino-terminal TRIM motif,
comprising RING, B-box and coiled-coil domains, and encodes
a unique SPRY (B30.2) domain (Reymond et al., 2001). Several
recombinant studies of human and rhesus monkey TRIM5α
have shown that the determinant of the species specificity lies in
the SPRY domain of TRIM5α (Perez-Caballero et al., 2005;
Sawyer et al., 2005; Stremlau et al., 2005; Yap et al., 2005). We
also previously demonstrated that 17-amino-acid residues and
adjacent AGM-specific 20-amino-acid duplication in the SPRY
domain determined species-specific restriction of SIVmac
(Nakayama et al., 2005). It is known that the RING and B-box
domains are required for restriction and that the coiled-coil
domain is required for multimerization (Stremlau et al., 2004;
Berthoux et al., 2005; Perez-Caballero et al., 2005; Nakayama
et al., 2006). TRIM5α is thought to bind HIV capsid and
promote its rapid, premature disassembly in ubiquitin dependent
448 K. Kono et al. / Virology 373 (2008) 447–456and independent manners (Stremlau et al., 2006; Diaz-Griffero
et al., 2006; Wu et al., 2006; Anderson et al., 2006). This means
that the viral RNA and proteins are exposed to cellular proteins
and degraded before nuclear transportation.
HIV-2 has a genome extremely similar to that of SIVmac
(Hahn et al., 2000). In contrast with the many reports con-
cerning HIV-1 and SIVmac, there have been only a few on
susceptibility of HIV-2 to TRIM5α from various species
(Nakayama et al., 2005; Ylinen et al., 2005). We previously
evaluated eight HIV-2 isolates for their sensitivity to
cynomolgus monkey TRIM5α and found that viruses carrying
proline at the 119th or 120th position of the capsid protein (CA)
were sensitive to cynomolgus monkey TRIM5α, whereas those
with either alanine or glutamine were resistant (Song et al.,
2007). In the study presented here, we tested these HIV-2
isolates for their sensitivity to another OWM rhesus monkey
TRIM5α and found that both cynomolgus monkey TRIM5α-
sensitive and -resistant viruses were restricted by rhesus
monkey TRIM5α. We were able to show that three amino
acid residues TFP at the 339th to 341st positions of rhesus
monkey TRIM5α are important for restriction activity against
HIV-2 strains.Fig. 1. Alignments of amino acid sequences of cynomolgus monkey (CM) and rhes
domains are indicated by labeled bars over the sequence. Variable region 1 is indicated
to the one of cynomolgus monkey TRIM5α and dashes a lack of the amino acid residu
that are important for rhesus monkey TRIM5α restriction activity against HIV-2 strResults
Rhesus monkey TRIM5α inhibits both cynomolgus monkey
TRIM5α-sensitive and -resistant HIV-2 viruses
Wepreviously reported that HIV-2 isolates carrying proline at
the 120th position of CAwere sensitive to cynomolgus monkey
TRIM5α, whereas those with either alanine or glutamine were
resistant. Both cynomolgus and rhesus monkey TRIM5αs are
known to restrict HIV-1 but not SIVmac. Predicted amino acid
sequences of cynomolgus and rhesus monkey TRIM5α are
shown in Fig. 1. Rhesus and cynomolgus monkey TRIM5α
share 96.8% of amino acid residues. To test these HIV-2 isolates
for their sensitivity to rhesus monkey TRIM5α, we constructed a
recombinant Sendai virus (SeV) expressing rhesus monkey
TRIM5α fused with the HA tag in the C-terminal. Western blot
analysis using an antibody against HA-tag showed that rhesus
monkey TRIM5α was expressed at similar levels to those of
cynomolgus monkey TRIM5α in recombinant SeV infected
human T-cell line MT4 cells (data not shown). Fluorescent
microscopic observation confirmed that these TRIM5αs were
detected in all the cells infected with recombinant SeVs (data notus monkey (Rh) TRIM5αs. The RING, B-box2, coiled-coil and SPRY (B30.2)
by a broken bar over the sequence. Dots denote the amino acid residues identical
e that is present in rhesus monkey TRIM5α. The box marks amino acid residues
ains (see Results).
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lacking the SPRY domain, CM SPRY(−) TRIM5α, as a negative
control. MT4 cells infected with recombinant SeV expressing
rhesus monkey TRIM5α, cynomolgus monkey TRIM5α, or CM
SPRY(−) TRIM5α were then superinfected with an X4-tropic
HIV-1 strain NL43, SIVmac239, HIV-2 strain GH123, or
GH123/Q which is a mutant HIV-2 carrying glutamine (Q) at the
120th position of CA. In agreement with the results of previous
studies, rhesus and cynomolgus monkey TRIM5α could restrict
HIV-1 NL43, but failed to restrict SIVmac239 (Fig. 2, upper
panels). HIV-2 GH123, cynomolgus monkey TRIM5α-sensitive
strain, was restricted by both rhesus and cynomolgus monkey
TRIM5αs (Fig. 2, lower left panel), which is also consistent with
the findings of previous studies (Song et al., 2007). Despite a
high degree of sequence similarity between rhesus and cyno-
molgus monkey TRIM5αs, rhesus monkey TRIM5α could in-
hibit replication of HIV-2 GH123/Q, the strain resistant to
cynomolgus monkey TRIM5α (Fig. 2, lower right panel).
Variable region 1 (V1) of SPRY (B30.2) domain of rhesus monkey
TRIM5α is a determinant for restriction of HIV-2 GH123/Q
infection
It is known that the variable region 1 (V1) (Song et al.,
2005a,b) of the rhesus monkey TRIM5α SPRY domain is the
major determinant of anti-HIV-1 potency (Perez-CaballeroFig. 2.MT4 cells infectedwith recombinant SeVexpressing rhesusmonkey (Rh;○), cy
HIV-1 NL43, SIVmac239, HIV-2 GH123, or HIV-2 GH123/Q. Culture supernatants
mutant virus carrying glutamine (Q) at the 120th position of HIV-1 GH123 capsid. Cet al., 2005; Sawyer et al., 2005; Stremlau et al., 2005; Yap
et al., 2005). To determine the precise region of TRIM5α res-
ponsible for the anti HIV-2 GH123/Q activity of rhesus monkey
TRIM5α, we constructed a recombinant SeV expressing chi-
meric TRIM5αs between rhesus and cynomolgus monkey
TRIM5α by using SphI and BamHI restriction enzyme digestion
(Fig. 3A). The central fragment comes from SphI and BamHI
digestion contains the V1 of SPRY domain (Fig. 1).
As expected, all forms of chimeric TRIM5α inhibited HIV-1
NL43 and HIV-2 GH123 replication, although the extent of
inhibition of HIV-2 GH123 varied among chimeric TRIM5αs
(Fig. 3B, left and center panel). On the other hand, 212, 112, and
211 chimeric TRIM5α restricted HIV-2 GH123/Q infection,
whereas 121, 221, and 122 chimeric TRIM5α did not (Fig. 3B,
right panel), although the expression levels of the latter 1 day
after SeV infection were not lower than those of parental and
other chimeric TRIM5αs (Fig. 3C). Furthermore, these chimeric
TRIM5α expression levels at day 6 after SeV infection were
almost equivalent to those at day 1 after SeV infection (data not
shown). These results confirmed that stability and kinetics
of expression were similar among these chimeric TRIM5αs.
Since 212,112, and 211 chimeric TRIM5α possess the rhesus
monkey TRIM5α V1, those results indicated that the rhesus
monkey TRIM5α V1 is a determinant of anti HIV-2 GH123/Q
activity. It is noteworthy that cynomolgus monkey TRIM5α-
sensitive HIV-2 GH123 grew to slightly higher titers in the cellsnomolgusmonkey (CM;▴), or CMSPRY(−) (□) TRIM5αwere inoculatedwith
were respectively assayed for levels of p24, p27, or p25. HIV-2 GH123/Q is a
M SPRY(−) TRIM5α served as negative control.
Fig. 3. (A) Schematic representation of chimeric TRIM5αs and summary of the results.White and black bars denote rhesusmonkey (Rh) and cynomolgusmonkey (CM)
sequences, respectively. +++, ++, +, and − denote more than 1000-fold, 100- to 1000-fold, 8- to 100-fold, and less than 8-fold suppression of virus growth, respectively,
compared with the negative control on day 6. (B) MT4 cells were infected with recombinant SeVexpressing 121 (■), 212 (□), 112 (▴), 221 (▵), 122 (●), 211 (○), 111
(Rh) (♦), 222 (CM) (⋄), or CM SPRY(−) (⁎) TRIM5α. Nine hours after infection, cells were inoculated with HIV-1 NL43, HIV-2 GH123, or HIV-2 GH123/Q viruses.
Culture supernatants were respectively assayed for levels of p24 or p25. (C) Twenty-four hours after SeV infection, TRIM5α proteins in lysates of MT4 cells infected
with recombinant SeVexpressing 121, 212, 112, 221, 122, 211, 111 (Rh), or 222 (CM) TRIM5αwere visualized byWestern blotting with an antibody against HA-tag.
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sing parental cynomolgus monkey or 122 chimeric TRIM5α
(Fig. 3B, center panel). These results indicate that the extent of
inhibition of HIV-2 GH123 by chimeric 121 and 221 TRIM5αs
is slightly less than that by parental cynomolgus monkey and
122 chimeric TRIM5α. It has been reported that all three varia-
ble regions (V1–V3) could contribute to the anti-viral activity of
TRIM5α (Ohkura et al., 2006). It is possible that the combi-
nation of the cynomolgus monkey TRIM5α V1 and the rhesus
monkey TRIM5α C-terminal portion of the SPRY domain
slightly impairs the anti-HIV-2 function of TRIM5α.
V1 of SPRY domain of rhesus monkey TRIM5α is a determinant
for broader and more potent anti-HIV-2 activity
To examine the restriction activities of rhesus monkey
TRIM5α against other HIV-2 strains, we tested HIV-2 UC2,HIV-2 UC12, and HIV-2 UC14 for their growth potential in
human T-cell line Hut78 infected with SeVexpressing 121, 212,
111 (rhesus monkey; Rh), 222 (cynomolgus monkey; CM), or
SPRY(−) TRIM5α. As shown in Fig. 4, rhesus monkey
TRIM5α and cynomolgus monkey chimeric TRIM5α contain-
ing the V1 of rhesus monkey TRIM5α (212) completely res-
tricted HIV-2 UC2 and HIV-2 UC14, whereas cynomolgus
monkey TRIM5α and rhesus monkey chimeric TRIM5α con-
taining the V1 of cynomolgus monkey TRIM5α (121) failed to
do so. Rhesus monkey TRIM5α and 212 chimeric TRIM5α also
completely restricted HIV-2 UC12, while cynomolgus monkey
TRIM5α did so partially, which is consistent with our previous
findings (Song et al., 2007). 121 chimeric TRIM5α showed very
weak restriction activity on replication of HIV-2 UC12. Putting
these findings together leads us to conclude that the V1 is a
determinant for broader and more potent anti-HIV-2 activity of
rhesus monkey TRIM5α.
Fig. 4. Hut78 cells infected with recombinant SeVexpressing 121 (○), 212 (●),
111 (Rh) (□), 222 (CM) (▴) or CM SPRY(−) (▵) TRIM5α. Cells were super-
infected with HIV-2 isolates, UC2, UC14, or UC12. Culture supernatants were
assayed for levels of p25.
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monkey TRIM5α are important for inhibiting HIV-2 GH123/Q
replication
As shown in Fig. 1, the V1 of the SPRY domain of rhesus
monkey TRIM5α contains two amino acid residues TF that are
not present in cynomolgus monkey TRIM5α. To examine
whether these two additional amino acid residues are responsible
for the broad anti-HIV-2 activity of rhesus monkey TRIM5α, we
constructed a recombinant SeV expressing rhesus monkey
TRIM5α lacking these two amino acid residues (Rh deltaTF
TRIM5α). We also constructed a SeVexpressing mutant rhesus
monkey TRIM5α in which amino acid residues TFP at the 339th
to 341st positions were replaced with a single amino acid Q
found in cynomolgus monkey TRIM5α (Rh TFP-Q TRIM5α)
(Fig. 5A). Expression levels of mutant TRIM5αs in MT4 cells
infected with these SeVs were comparable to those of parental
TRIM5αs (Fig. 5B).
As shown in Fig. 5C, both of the mutant rhesus monkey
TRIM5αs restricted HIV-1 infection. In the case of HIV-2, Rh
deltaTF TRIM5α inhibited both HIV-2 GH123 and HIV-2
GH123/Q replications, although anti-HIV-2 activity was slightly
weaker than that of parental rhesus monkey TRIM5α. On the
other hand, Rh TFP-QTRIM5α lost its inhibitory activity against
HIV-2 GH123/Q, while it could suppress replication of HIV-2
GH123 to the same extent as it was suppressed by 121 chimeric
TRIM5α. Conversely, cynomolgusmonkey TRIM5α possessing
TFP instead of Q at the 339th position (CM Q-TFP TRIM5α)
completely restricted HIV-2 GH123/Q replication (Fig. 5D).
These results indicated that these three amino acids are important
for restricting HIV-2 GH123/Q by rhesus monkey TRIM5α.
Baboon TRIM5α V1 confers anti-viral activity against HIV-2
GH123/Q to cynomolgus monkey TRIM5α, whereas sooty
mangabey and pig-tailed monkey TRIM5α V1 fail to do so
HIV-2 is thought to originate from the simian immunodefi-
ciency virus of sooty mangabeys (Hahn et al., 2000). Several
HIV-2 isolates could grow in baboon and pig-tailed monkey, and
some of them were reported to cause an AIDS-like disease in
these animals (Barnett et al., 1994; Locher et al., 1998; Locher
et al., 2001; McClure et al., 2000). To assess anti-HIV-2 activity
of these OWMs TRIM5αs, we constructed a recombinant SeV
expressing cynomolgus monkey chimeric TRIM5α containing
the V1 of baboon (2B2), sooty mangabey (2S2), or pig-tailed
monkey (2P2) TRIM5α (Fig. 6A). Expression levels of these
chimeric TRIM5αs in MT4 cells infected with the SeVs were
comparable to those of parental cynomolgus monkey TRIM5α
(Fig. 6C). The amino acid sequences of the V1 of baboon, sooty
mangabey, and pig-tailed monkey TRIM5α are shown in
Fig. 6B. Baboon and sooty mangabey TRIM5α show the SFP
sequence at the 339th to 341st positions, whereas pig-tailed
monkey TRIM5α has a single Q as cynomolgus monkey
TRIM5α. As shown in Fig. 6D, all the chimeric TRIM5αs con-
taining the V1 of baboon, sooty mangabey, and pig-tailed
monkey TRIM5α restricted HIV-1 infection. These results are
consistent with those of previous studies (Kaiser et al., 2007;Newman et al., 2006; Ohkura et al., 2006). In the case of HIV-2,
there were wide variations in anti-HIV-2 activity by the chimeric
TRIM5αs. Chimeric TRIM5α containing baboon V1 inhibited
both HIV-2 GH123 and HIV-2 GH123/Q replications, while
chimeric TRIM5α containing sooty mangabey V1 partially
inhibited HIV-2 GH123 and only slightly inhibited HIV-2
GH123/Q replication. Finally, chimeric TRIM5α containing
pig-tailed monkey V1 only slightly inhibited both HIV-2 GH123
and HIV-2 GH123/Q replication. This shows that there is a lack
of correlation between the effects of various TRIM5αs on HIV-2
Fig. 5. (A)Mutant Rh deltaTF TRIM5αwas generated by deleting 339th-TF-340th andmutant Rh TFP-Q TRIM5αwas generated by replacing 339th-TFP-341st with Q by
site-directedmutagenesis. Dots denote amino acid identity, dashes a lack of the amino acids residue present only in rhesusmonkey (Rh) TRIM5α, and +++, ++, +, and−more
than 1000-fold, 100- to 1000-fold, 8- to 100-fold, and less than 8-fold suppression of virus growth, respectively, compared with the negative control on day 6. (B) Twenty-
four hours after SeV infection, TRIM5α proteins in lysates of MT4 cells infected with recombinant SeVexpressing 121, Rh delta TF, Rh TFP-Q, 111 (Rh), or 222 (CM)
TRIM5αwere visualized byWestern blotting with an antibody against HA-tag. (C)MT4 cells were infectedwith recombinant SeVexpressing 121 (■), Rh delta TF (□), Rh
TFP-Q (▴), 111 (Rh) (▵), 222 (CM) (●), or CM SPRY(−) (○) TRIM5α. Nine hours after infection, cells were inoculated with HIV-1 NL43, HIV-2 GH123, or HIV-2
GH123/Q viruses. Culture supernatants were respectively assayed for levels of p24 or p25. (D) MT4 cells were infected with recombinant SeVexpressing CMQ-TFP (♦),
111 (Rh) (▵), 222 (CM) (●), or CMSPRY(−) (○) TRIM5α. Nine hours after infection, cells were inoculated with HIV-1 NL43, HIV-2GH123, or HIV-2GH123/Q viruses.
Culture supernatants were respectively assayed for levels of p24 or p25.
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blood mononuclear cells.
Discussion
In the study presented here, we found that rhesus monkey
TRIM5α showed anti-HIV-2 activity broader and more potent
than that of cynomolgus monkey.Wewere also able to show that
three amino acid residues TFP at the 339th to 341st positions in
the V1 were important for the broad HIV-2 restriction activity ofrhesus monkey TRIM5α. Previous studies have shown that the
V1 of TRIM5α determines species-specific restriction of HIV-1
and SIVmac (Perez-Caballero et al., 2005; Sawyer et al., 2005;
Stremlau et al., 2005; Yap et al., 2005; Nakayama et al., 2005).
Ours is the first study to demonstrate that the V1 of TRIM5α also
determines anti-HIV-2 potency. Since MT4 and Hut78 cells
express endogenous human TRIM5α, it is possible that endo-
genous human TRIM5α interfere with exogenous TRIM5α.
However, the expression level of SeV-derived TRIM5α is more
than 100 times higher than that of endogenous TRIM5α (data
453K. Kono et al. / Virology 373 (2008) 447–456not shown), and the effect of endogenous TRIM5α is therefore
considered to be negligible.
A previous study using a human and rhesus monkey
chimeric TRIM5α revealed that a single amino acid substitution
from R to P at the 332nd position of human TRIM5α (corre-
sponding to the 334th position in rhesus monkey TRIM5α)
confers strong anti-HIV-1 activity to human TRIM5α (Stremlau
et al., 2005; Yap et al., 2005). We found that rhesus monkey
TRIM5α and chimeric TRIM5α containing baboon V1 strongly
restricted HIV-2 GH123/Q, while chimeric TRIM5α containing
sooty mangabey V1 did so only slightly, although baboon andFig. 6. (A) Schematic representation of chimeric TRIM5α and summary of the resul
sequences, respectively. B, S, and P denote sequence from baboon, sootymangabey, and
1000-fold, 8- to 100-fold, and less than 8-fold suppression of virus growth, respectively, c
of the V1 and franking region within the SPRY domain of cynomolgus monkey, pigtaile
by a bar over the sequence. The first box indicates the amino acid residues that were re
residues that are important for restricting HIV-2 strains which are resistant to cynomolgus
lysates ofMT4 cells infectedwith recombinant SeVexpressing 222 (CM), 212, 2B2, 2S2
tag. (D) MT4 cells were infected with recombinant SeVexpressing 222 (CM) (■), 212
infection, cells were inoculated with HIV-1 NL43, HIV-2 GH123, or HIV-2 GH123/Q,sooty mangabey TRIM5α share the SFP motif at the 339th to
341st positions. Rhesus monkey and baboon TRIM5α possess
P, whereas human and sooty mangabey TRIM5α possess R at
the 334th position. On the other hand, cynomolgus monkey
TRIM5α strongly restricted HIV-2 GH123, while chimeric
TRIM5α containing pig-tailed monkey V1 did so only slight-
ly. Cynomolgus monkey TRIM5α possesses P, whereas pig-
tailed monkey TRIM5α possesses Q at the 334th position.
These results indicate the P residue at the 334th position of
primate TRIM5α also plays a critical role in the restriction of
HIV-2.ts. White and black bars denote rhesus monkey and cynomolgus monkey (CM)
pig-tailedmonkey, respectively, and +++, ++, +, and−more than 1000-fold, 100- to
omparedwith the negative control on day 6. (B)Alignment of amino acid sequences
d monkey, rhesus monkey, baboon, and sooty mangabey TRIM5αs. V1 is indicated
ferred to as site 332 in the human TRIM5α. The second box indicates amino acid
monkey TRIM5α. (C) Twenty-four hours after SeVinfection, TRIM5α proteins in
, or 2P2TRIM5αwere visualized byWestern blottingwith an antibody against HA-
(□), 2B2 (▴), 2S2 (▵), 2P2 (●), or CM SPRY(−) (○) TRIM5α. Nine hours after
viruses. Culture supernatants were respectively assayed for levels of p24 or p25.
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mangabey (SIVsmm) (Hahn et al., 2000). Our results showed that
HIV-2 GH123 replication was partially inhibited by chimeric
TRIM5α containing sooty mangabey V1, while HIV-2 GH123/Q
grew strongly in the presence of the chimeric TRIM5α. This
result is consistent with the fact that all SIVsmm sequences in the
Los Alamos database possess Q or A at the 119th or 120th
position of CA (Song et al., 2007). On the other hand, chimeric
TRIM5α containing sooty mangabey V1 has a strong anti-HIV-1
activity, even though it has R at the 334th position as in human
TRIM5α. Sooty mangabey TRIM5α, on the other hand, posses-
ses the SFPmotif at the 339th to 341st positions. Yap et al. (2005)
showed that human TRIM5α carrying the rhesus monkey
sequence LFTFPSLT which included the TFP motif instead of
the human sequence RYQTFV at the 335th to 340th positions
could restrict HIV-1. These results thus indicate that the TFP or
SFP motif at the 339th to 341st positions can confer anti-HIV-1
activity as well as the P residue at the 334th position.
In the case of pig-tailed monkey, which could develop an
AIDS-like disease by HIV-2 (McClure et al., 2000), anti-HIV-2
activity of chimeric TRIM5α containing pig-tailed monkey V1
was very weak. Furthermore, after we completed this study, it
was reported that pig-tailed monkeys lack expression of
TRIM5α. Instead, pig-tailed monkeys express TRIM5θ and
TRIM5η, novel TRIM5 isoforms lacking anti-HIV-1 activity
(Brennan et al., 2007). These findings are probably account for
the fact that pig-tailed monkey can be used as an AIDS model.
Previous studies showed that rhesusmonkey aswell as baboon
can be infected with HIV-2 (Dormant et al., 1989; Franchini et al.,
1989; Nicol et al., 1989; Franchini et al., 1990; Castro et al.,
1991), while the latter can also develop an AIDS-like disease as a
result of HIV-2 infection (Barnett et al., 1994; Locher et al., 1998;
Locher et al., 2001). In our study, however, rhesus monkey
TRIM5α and chimeric TRIM5α containing baboon V1 could
strongly inhibit HIV-2 replication. The reason why HIV-2 can
replicate in rhesusmonkey and baboon, even though the TRIM5α
of these monkey species possesses strong anti-HIV-2 activity, is
unclear at present. The presence of TRIM5α mRNA in cells of
rhesus monkey and baboon cells has been confirmed (Stremlau
et al., 2004; Kaiser et al., 2007). It is also known that TRIM5α
exhibits a high degree of sequence variation even within species.
In rhesus monkey, there is a 339th-TFP-341st to Q polymorphism
which diminishes the anti HIV-2 GH123/Q activity of rhesus
monkey TRIM5α (Newman et al., 2006) (Fig. 5). It is thus
possible that rhesus monkey carrying this polymorphism in the
TRIM5α gene could be infected with HIV-2 and that a number of
baboons have similar polymorphisms. It would be interesting to
investigate the effect of genetic polymorphisms in baboon
TRIM5α on its restriction activity against HIV-2.
Materials and methods
Cloning and expression of TRIM5α
Rhesus monkey TRIM5α cDNAwas amplified by RT-PCR of
mRNA extracted from rhesus monkey kidney LLC-MK2 cells
using 5′-GCGGCCGCTACTATGGCTTCTGG-3′ as the forwardprimer and 5′-GAATTCTCAAGAGCTTGGTGA-3′ as the re-
verse primer. Amplified products were then cloned into the vector
pCR-2.1TOPO (Invitrogen, Carlsbad, CA) and the nucleotide
sequence authenticity was verified. For generating rhesus mon-
key TRIM5α cDNA carrying an HA tag (YPYDVPDYAA) at its
C-terminus (Rh-TRIM5α-HA), cloned rhesus monkey TRIM5α
cDNA in pCR-2.1TOPO was used as a template for PCR-ampli-
ficationwith a primer (5′-TCAAGCAGCATAATCAGGAACAT-
CATAAGGATAAGAGCTTGGTGAGCACAGAG-3′) contain-
ing a nucleotide sequence corresponding to the HA-tag
(underline) fused with the C-terminal portion of TRIM5α. The
C-terminal portion of TRIM5α fused with the HA-tag (BamHI to
NotI) and theN-terminal portion of TRIM5α (NotI toBamHI)was
assembled on a pCEP4 vector (Invitrogen). Construction of cyno-
molgus monkey TRIM5α carrying an HA tag at the C-terminus
(CM-TRIM5α-HA) was described previously (Nakayama et al.,
2005).
To generate 121 chimeric TRIM5α, the 188-bp SphI–BamHI
fragment of rhesus monkey TRIM5α was replaced with the
corresponding 182-bp SphI–BamHI fragment of cynomolgus
monkey TRIM5α in the background of Rh-TRIM5α-HA.
Conversely, the 182-bp SphI–BamHI fragment of cynomolgus
monkey TRIM5α was replaced with the 188-bp SphI–BamHI
fragment of rhesus monkey TRIM5α in the background CM-
TRIM5α-HA to generate 212 chimeric TRIM5α. To generate
112 chimeric TRIM5α, the C-terminal portion of CM-TRIM5α-
HA (BamHI to NotI) and the N-terminal portion of rhesus
monkey TRIM5α were assembled on a pcDNA3.1 (−) vector
(Invitrogen). Conversely, the C-terminal portion of Rh-
TRIM5α-HA (BamHI to NotI) and the N-terminal portion of
cynomolgus monkey TRIM5α (NotI to BamHI) were assembled
on a pcDNA3.1 (−) vector to generate 221 chimeric TRIM5α.
To generate 122 chimeric TRIM5α, the C-terminal portion of
CM-TRIM5α-HA (SphI to NotI) and the N-terminal portion of
rhesus monkey TRIM5α (NotI to SphI) were assembled on a
pcDNA3.1 (−) vector. Conversely, the C-terminal portion of Rh-
TRIM5α-HA (SphI to NotI) and the N-terminal portion of
cynomolgus monkey TRIM5α (NotI to SphI) were assembled
on a pcDNA vector to generate 211 chimeric TRIM5α.
Mutant rhesus monkey TRIM5α lacking two amino acid
residues TF at the 339th to 340th positions (Rh deltaTF
TRIM5α), mutant rhesus monkey TRIM5α in which amino
acid residues TFP at the 339th to 341st positions was replaced
with a single amino acid Q found in cynomolgus monkey
TRIM5α (Rh TFP-QTRIM5α), andmutant cynomolgusmonkey
TRIM5α in which a single amino acid Q at the 339th positionwas
replaced with three amino acid residues TFP found in rhesus
monkey TRIM5α (CM Q-TFP TRIM5α) were generated by site-
directed mutagenesis by PCR-mediated overlap primer exension
method (Ho et al., 1989). Briefly, two DNA fragments with
overlapping ends were generated by using the outer primers and
the complementary primers with overlapping complementary
nucleotides containing desired mutations. The resultant
two fragments were combined in the subsequent fusion reaction
in which the overlapping ends anneal, allowing the 3′ overlap
of each strand to serve as a primer for 3′ extension of the com-
plementary strand. The outer primers for generating Rh deltaTF
455K. Kono et al. / Virology 373 (2008) 447–456TRIM5α were 5′-GCGGCCGCTACTATGGCTTCTGG-3′ and
5′-GAATTCTCAAGAGCTTGGTGA-3′, and the complemen-
tary primers were 5′-GGGACATTATTTCCGTCACTCACG-3′
and 5′-CGTGAGTGACGGAAATAATGTCCC-3′. The outer
primers were common in all cases of PCR-based mutagenesis
of TRIM5α. The complementary primers for Rh TFP-Q TRIM5α
were 5′-GGGACATTATTTCAATCACTCACG-3′ and 5′-
CGTGAGTGATTGAAATAATGTCCC-3′ (underline; TFP-Q
site), and 5′-GGACATTATTTACGTTTCCGTCACTCACG-3′
and 5′-CGTGAGTGACGGAAACGTAAATAATGTCC-3′
(underline; Q-TFP site) for CM Q-TFP TRIM5α.
2B2, 2S2, and 2P2 chimeric TRIM5α, which possessed the 188-
bpSphI–BamHI fragment of baboon TRIM5α, 188-bp fragment of
sooty mangabey TRIM5α, and 182-bp fragment of pig-tailed
monkey TRIM5α, respectively, in the background of CM-
TRIM5α-HA were generated by the same method as described
above. To obtain SphI–BamHI fragments of baboon and sooty
mangabey TRIM5αs, cloned rhesus monkey TRIM5αwas used as
a template for PCR-amplification with outer primers described
above and complementary primers containing a nucleotide se-
quence corresponding to the 330th to 339th amino acid residues of
baboon TRIM5α (5′-CAGATAACGTATCAGGCACCAGGGA-
CATTATTTTCGTTTCCG-3′ and 5′-CGGAAACGAAAATA-
ATGTCCCTGGTGCCTGATACGTTATCTG-3′) and the 334th
to 343rd amino acid residues of sooty mangabey TRIM5α (5′-
CAGGCACGAGGGACATTATTTTCGTTTCCGTCAC-
ACACGAAT-3′ and 5′-ATTCGTGTGTGACGGAAACGA-
AAATAATGTCCCTCGTGCCTG-3′), respectively. To obtain
the SphI–BamHI fragment of pig-tailed TRIM5α, cloned cyno-
molgus monkey TRIM5α was used as a template for PCR-
amplification with outer primers described above and complemen-
tary primers containing a nucleotide sequence corresponding to the
330th to 350th amino acid residues of pig-tailed monkey TRIM5α
(5′-CAGTCACTCACGAATTTCATTTATTGTACTGG-
CATCCTGGGC-3′ and 5′-CGTGAGTGACTGAAATAATGTC-
CCTTGTGTCCGATACATTATCTG-3′). The entire coding
sequences of those TRIM5α were then transferred to the NotI site
of pSeV18+b(+). Recombinant SeVs carrying various TRIM5α
were recovered according to a previously described method
(Nakayama et al., 2005). The viruses passaged twice in embryo-
nated chicken eggs were used as stock for all experiments.
Viral infection
2×105 MT4 or Hut78 cells were infected with SeV expres-
sing each TRIM5α at a multiplicity of infection of 10 plaque-
forming units per cell and incubated at 37 °C for 9 h. Cells were
then superinfected with 20 ng of p24 of HIV-1 NL43, 20 ng of
p27 of SIVmac239, or 20 ng of p25 of HIV-2 GH123, GH123/Q,
or other HIV-2 isolates. The culture supernatants were collected
periodically, and the level of p24, p27, or p25was measured with
a RETROtek antigen ELISA kit (ZeptoMetrix, Buffalo, NY).
Western blot analysis
MT4 cells infected with recombinant SeVs expressing HA-
tagged TRIM5α proteins were lysed in lysis buffer (50 mMTris–HCl, pH 7.5, 150 mM NaCl, 1% Nonident P40, 0.5%
sodium deoxycholate). TRIM5α proteins in the lysates were
subjected to sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis (SDS-PAGE). Proteins in the gel were then electro-
nically transferred to a membrane (Immobilion; Millipore,
Billerica, MA). Blots were blocked and probed with anti-HA
high affinity rat monoclonal antibody (Roche, Indianapolis, IN)
overnight at 4 °C. Blots were then incubated with peroxidase-
conjugated anti-rat IgG (American Qualex, San Clemente, CA),
and bound antibodies were visualized with a Chemilumi-One
chemiluminescent kit (Nacalai Tesque, Kyoto, Japan).
TRIM5α cDNA sequences
TRIM5α cDNA sequences for rhesus monkey (AY523632),
cynomolgus monkey (AB210052), baboon (AY843505), sooty
mangabey (AY10303), and pig-tailed monkey (AY899887–
AY899893) were obtained from the GeneBank database.
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